Aiming at the target: improved adjuvant medical therapy

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Bedard, Philippe L ^a,b   Dinh, Phuong ^a,b   Sotiriou, Christos ^a,b,c   Piccart Gebhart, Martine J ^a,b,c  

^a JULES BORDET INSTITUTE   (Belgium)

^b Breast International Group   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Biomarkers; Breast cancer; Gene signatures; HER 2 erbB2; Target; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GOSERELIN; METHOTREXATE; MYC PROTEIN; TAMOXIFEN; TAU PROTEIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG RESPONSE; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS;

EID: 71749108799     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70268-1     Document Type: Article

References (58)

1. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 16 10 (2005 October 1) 1569-1583
2. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J., et al. Progress and promise: highlights of the International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007. Ann Oncol 18 7 (2007 July 1) 1133-1144
3. FDA. 510(k) Substantial equivalence determination decision summary. 2007 [cited 2008 October 3]; Available from: http://www.fda.gov/cdrh/reviews/K070675.pdf
4. bioMérieux. Three clinical studies of bioTheranostics Molecular Breast Cancer Diagnostics. Presented at San Antonio Breast Cancer Symposium 2009 [cited 2009 March 10]; Available from: http://www.biomerieux.com/servlet/srt/bio/portail/dynPage?open=PRT_NWS_REL&doc=PRT_NWS_REL_G_PRS_RLS_181.
5. Ipsogen. Improving the clinical value of tumor grading. 2008 [cited 2008 October 3]. Available from: http://www.ipsogen.com/breast-cancer-products/healthcare-professionnals/mapquant-dxgenomicgrade/
6. GenomicHealth. The role of Oncotype DX. 2008 [cited 2008 October 3]; Available from: http://www.genomichealth.com/oncotype/role/default.asp
7. Sotiriou C., and Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 360 8 (2009 February 19) 790-800
8. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev 7 7 (2007 Jul) 545-553
9. Gennari A., Sormani M.P., Pronzato P., Puntoni M., Colozza M., Pfeffer U., et al. HER-2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100 1 (2008 Jan 2) 14-20
10. Di Leo A., Isola J., Piette F., Ejlertsen B., Pritchard K.I., Bartlett J.M., et al. A metaanalysis of phase III trials evaluating the predictive value of HER-2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Res 69 (2009 January 15) 705 (2 - Meeting Abstracts):
11. Slamon D, Mackey J, Robert N, Crown J, Martin M, Eiermann W, et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: efficacy analyses determined by molecular subtypes of the disease. San Antonio Breast Cancer Symposium 2007: abstract #13.
12. Di Leo A., Gancberg D., Larsimont D., Tanner M., Jarvinen T., Rouas G., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 5 (2002 May) 1107-1116
13. Knoop A.S., Knudsen H., Balslev E., Rasmussen B.B., Overgaard J., Nielsen K.V., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 30 (2005 Oct 20) 7483-7490
14. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P., et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 24 16 (2006 Jun 1) 2428-2436
15. O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5) [abstract]. 2006 ASCO Annual Meeting Proceedings 2006; 24(18S [June 20 Supplement]):533.
16. Bartlett J., Munro A., Dunn J., Hiller L., Jordan S., Twelves C., et al. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEAT adjuvant breast cancer trial [abstract]. Cancer Res 69 (2009 January 15) 45 (2 - Meeting Abstracts)
17. Kim C, Bryant J, Horne Z, Geyer C, Wickerham D, Wolmark N, et al. Trastuzumab sensitivity of breast cancer with coamplification of HER-2 and cMYC suggests proapoptotic function of dysregulated cMYC in vivo. San Antonio Breast Cancer Symposium 2005; Abstract #46.
18. Perez E.A., Reinholz M.M., Dueck A.C., Wiktor A.E., Lingle W.L., Davidson N.E., et al. c-MYC amplification and correlation with patient outcome in early stage HER-2+ breast cancer from the NCCTG adjuvant intergroup trial N9831 [abstract]. Cancer Res 69 (2009 January 15) 56 (2 - Meeting Abstracts)
19. Andre F., Hatzis C., Anderson K., Sotiriou C., Mazouni C., Mejia J., et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13 7 (2007 Apr 1) 2061-2067
20. Pusztai L., Jeong J., Gong Y., Ross J.S., Kim C., Hortobagyi G.N., et al. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP B-28 randomized clinical trial [abstract]. Cancer Res 69 (2009 January 15) 54 (2 - Meeting Abstracts)
21. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006 December 14; Abstract #52.
22. Pritchard K.I., Messersmith H., Elavathil L., Trudeau M., O'Malley F., and Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26 5 (2008 Feb 10) 736-744
23. McArthur H.L., Tan L.K., Patil S., Wigler M., Hudis C.A., Hicks J., et al. High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER-2 co-amplification is uncommon in human breast cancer [abstract]. Cancer Res 69 (2009 January 15) 2023 (2 - Meeting Abstracts)
24. Liao D.J., and Dickson R.B. c-Myc in breast cancer. Endocrine-related Cancer 7 3 (2000 Sep) 143-164
25. Mamounas E.P., Bryant J., Lembersky B., Fehrenbacher L., Sedlacek S.M., Fisher B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23 16 (2005 June 1) 3686-3696
26. Tomasello G., de Azambuja E., Dinh P., Snoj N., and Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Rev Anticancer Ther 8 12 (2008 Dec) 1883-1890
27. Rouzier R., Rajan R., Wagner P., Hess K.R., Gold D.L., Stec J., et al. Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102 23 (2005 June 7) 8315-8320
28. Frasor J., Stossi F., Danes J.M., Komm B., Lyttle C.R., and Katzenellenbogen B.S. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 64 4 (2004 February 15) 1522-1533
29. Paik S., Kim C., and Wolmark N. HER-2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358 13 (2008 Mar 27) 1409-1411
30. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. N Engl J Med 353 16 (2005 October 20) 1673-1684
31. Wolff A.C., Hammond M., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 25 1 (2007 January 1) 118-145
32. Seidman A.D., Berry D., Cirrincione C., Harris L., Muss H., Marcom P.K., et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26 10 (2008 Apr 1) 1642-1649
33. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20 3 (2002 February 1) 719-726
34. van 't Veer L.J. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
35. Wang Y. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
36. Fan C. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355 (2006) 560-569
37. Desmedt C., Haibe-Kains B., Wirapati P., Buyse M., Larsimont D., Bontempi G., et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14 16 (2008 Aug 15) 5158-5165
38. Haibe-Kains B., Desmedt C., Piette F., Buyse M., Cardoso F., Van't Veer L., et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9 (2008) 394
39. Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., Haibe-Kains B., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10 4 (2008) R65
40. Loi S., Haibe-Kains B., Desmedt C., Lallemand F., Tutt A.M., Gillet C., et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25 10 (2007 Apr 1) 1239-1246
41. Knauer M., Cardoso F., Mook S., Bedard P., Koornstra R., Kok M., et al. Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature [abstract]. Breast Cancer Res 69 (2009 January 15) 4171 (2 - Meeting Abstracts)
42. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13 11 (2007 Jun 1) 3207-3214
43. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2008 Jul 27.
44. Dowsett M., Cuzick J., Wales C., Forbes J., Mallon L., Salter J., et al. Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study [abstract]. Cancer Res 69 (2009 January 15) 53 (2 - Meeting Abstracts)
45. Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). San Antonio Breast Cancer Symposium 2007; Abstract 10.
46. Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I, et al. The 70-gene MammaPrint profile allows to identify a subgroup of very good-prognostic patients with primary breast cancer and 4-9 positive lymph nodes. 2009 St Gallen Oncology Conference: Primary Therapy of Early Breast Cancer, St. Gallen, Switzerland 2009:S35. Abstract #71.
47. Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 23 (2006 Aug 10) 3726-3734
48. Pusztai L.H., Cardoso F., Sotiriou C., Lazar V., Piccart-Gebhart M., Hortobagyi G., et al. Combined use of genomic prognostic and treatment response predictors in breast cancer. J Clin Oncol 26 May 20 suppl (2008) abstr 527.
49. Dowsett M., Allred C., Knox J., Quinn E., Salter J., Wale C., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26 7 (2008 March 1) 1059-1065
50. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Postlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360 7 (2009 February 12) 679-691
51. Sparano J.A., and Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26 5 (2008 Feb 10) 721-728
52. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., and Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 26 5 (2008 Feb 10) 729-735
53. Bonnefoi H., Zimmer A.S., Piccart M., Mauriac L., Campone M., Tubiana-Hulin M., et al. P53 functional assay in yeast: evaluation in 1856 patients in a large prospective clinical trial (EORTC 10994/BIG 00-01) [abstract]. Cancer Res 69 (2009 January 15) 1067 (2 - Meeting Abstracts)
54. Potti A., Dressman H.K., Bild A., Riedel R.F., Chan G., Sayer R., et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12 11 (2006 Nov) 1294-1300
55. Bonnefoi H. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8 (2007) 1071-1078
56. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15 1 (2009 Jan) 68-74
57. Desmedt C., Azambuja E., Larsimont D., Delaloge S., Duhem C., Rouas G., et al. Investigating the predictive value of topoisomerase II alpha (TOP2A) gene, mRNA and protein levels in anthracycline-treated estrogen receptor (ER) negative breast cancer (BC) patients [abstract]. J Clin Oncol 26 15 suppl (2008 May 20) 11065
58. Johnston S.R., Leary A., Martin L.A., Smith I.E., and Dowsett M. Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?. Cancer 112 3 Suppl (2008 Feb 1) 710-717